![](/img/cover-not-exists.png)
Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
Wan, Ning, Zhang, Tian‐tian, Hua, Si‐hua, Lu, Zi‐luo, Ji, Bo, Li, Li‐xia, Lu, Li‐qing, Huang, Wen‐jie, Jiang, Jie, Li, JianLanguage:
english
Journal:
Cancer Medicine
DOI:
10.1002/cam4.2793
Date:
January, 2020
File:
PDF, 1003 KB
english, 2020